President Trump’s executive order suspending federal funding for gain-of-function research not only contains questionable assertions, but it also frames the targeted research so broadly that it is likely to affect even lower-risk infectious disease research.
Related Posts
Build Your Healthcare Brand & Stay Connected to Customers
After a speaking with dozens of healthcare executives during my recent conference tour, I’m more convinced than ever— Brand strategy isn’t optional. It’s a business […]
Overview of President Trump’s Executive Actions on Global Health
January 20, 2025 Initial Rescissions Of Harmful Executive Orders And Actions PURPOSE: Initial rescissions of Executive Orders and Actions issued by President Biden. Among these […]
When Drug Price Transparency Isn’t Enough – The Health Care Blog
By KRISTINA SMITH & PHIYEN NGUYEN Policymakers and advocates often promote drug price transparency to lower costs and improve equity. While transparency is an important […]